ProQR Therapeutics reported a net loss of 13 million euros, or 0.33 euros per diluted share, in the fourth quarter of 2018 compared with a net loss of 11.3 million euros, or 0.39 euros per diluted share, in 2017’s final quarter, according to a press release.
For the full year, net loss totaled 37.1 million euros, or 1.09 euros per diluted share, compared with a net loss of 43.7 million euros, or 1.72 euros per diluted share, for 2017.
Research and development costs increased from 8.3 million euros to 9.5 (Read more...)
Uncategorized